by EmpathiCSubstanceS | Apr 25, 2021 | Addiction, Cannabis Marijuana
A first-of-its-kind exploratory study, led by researchers from Yale School of Medicine, has found a single dose of the psychedelic psilocybin can reduce migraine frequency by 50 percent for a least two weeks. The preliminary trial was small, with follow-up work...
by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana
A novel study investigating the effects of cannabis on driving in a real-world context has found cannabidiol (CBD) alone does not impair driving ability. The landmark finding promises to be invaluable in guiding road safety regulations as cannabis laws shift across...
by EmpathiCSubstanceS | Apr 25, 2021 | MDMA Sassafras Molly
In the late 1970s and early 1980s MDMA was often utilized to help facilitate positive results in couples counseling. A few dozen pioneering psychotherapists in the United States explored the drug’s therapeutic uses until the US government declared MDMA a Schedule 1...
by EmpathiCSubstanceS | Apr 25, 2021 | Psychedelic Medicine
Surfing the wave of novel research into medical uses for psychedelic compounds, the Icahn School of Medicine at Mount Sinai has launched a dedicated psychedelic center focusing initially on the study of MDMA and psilocybin for PTSD and other stress-related conditions...
by EmpathiCSubstanceS | Apr 25, 2021 | Cannabis Marijuana, MDMA Sassafras Molly
A team of Australian scientists has demonstrated a novel microencapsulation method designed to improve the absorption and bioavailability of cannabidiol (CBD). Animal tests suggest the new method increases peak concentrations of CBD in the brain by 300 percent...
